A Phase 1b, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 598 in Subjects With Obesity
Phase of Trial: Phase I
Latest Information Update: 02 Jan 2019
At a glance
- Drugs AMG 598 (Primary) ; Liraglutide (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Amgen
- 06 Dec 2018 Planned End Date changed from 11 May 2020 to 16 Dec 2019.
- 06 Dec 2018 Planned primary completion date changed from 11 May 2020 to 16 Dec 2019.
- 06 Dec 2018 Status changed from not yet recruiting to recruiting.